{"id":819067,"date":"2025-02-27T07:36:35","date_gmt":"2025-02-27T12:36:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\/"},"modified":"2025-02-27T07:36:35","modified_gmt":"2025-02-27T12:36:35","slug":"trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\/","title":{"rendered":"Trevi Therapeutics to Participate in Upcoming March Investor Conferences"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">NEW HAVEN, Conn.<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Feb. 27, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4371012-1&amp;h=57656658&amp;u=http%3A%2F%2Fwww.trevitherapeutics.com%2F&amp;a=Trevi+Therapeutics%2C+Inc.\" target=\"_blank\" rel=\"nofollow\">Trevi Therapeutics, Inc.<\/a>\u00a0(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC),\u00a0today announced that senior management will be attending the following investor conferences in March.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg\" title=\"Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto\/Trevi Therapeutics, Inc.)\" alt=\"Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto\/Trevi Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <b><br \/>\n          <u>TD Cowen 45<sup>th<\/sup> Annual Health Care Conference<br \/><\/u><br \/>\n        <\/b><br \/>\n        <span><br \/>\n          <span class=\"xn-chron\">March 3-5, 2025<\/span>, <span class=\"xn-location\">Boston, Massachusetts<\/span><br \/><\/span>Corporate Presentation: <span class=\"xn-chron\">March 4<\/span>, <span class=\"xn-chron\">10:30-11:00am ET<\/span><br \/><b>Trevi Representatives:<\/b>\u00a0Lisa Delfini, Chief Financial Officer, and Farrell Simon, Chief Commercial Officer<br \/>A Corporate presentation is available for in-person conference attendees.<\/p>\n<p>\n        <b><br \/>\n          <u>Leerink Partners Global Healthcare Conference<br \/><\/u><br \/>\n        <\/b><br \/>\n        <span><br \/>\n          <span class=\"xn-chron\">March 10-12, 2025<\/span>, <span class=\"xn-location\">Miami, Florida<\/span><br \/><\/span><br \/>\n        <b>Corporate Presentation:<\/b><br \/>\n        <span class=\"xn-chron\">March 12<\/span>, <span class=\"xn-chron\">8:00am ET<\/span><br \/><b>Trevi Representatives:<\/b>\u00a0Jennifer Good, President and CEO, and <span class=\"xn-person\">James Cassella<\/span>, Chief Development Officer<br \/>A Corporate presentation is available for in-person conference attendees.<\/p>\n<p>\n        <b><br \/>\n          <u>Leerink Partners Mountain Meeting<br \/><\/u><br \/>\n        <\/b><br \/>\n        <span><br \/>\n          <span class=\"xn-chron\">March 23-26, 2025<\/span>, <span class=\"xn-location\">Jackson Hole, Wyoming<\/span><br \/><\/span><br \/>\n        <b>Trevi Representative:<\/b>\u00a0Lisa Delfini, Chief Financial Officer<br \/>A Corporate presentation is available for in-person conference attendees.<\/p>\n<p>\n        <b>About Trevi Therapeutics, Inc.<br \/><\/b>Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), which are opioid receptors that play a key role in controlling cough hypersensitivity. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.\u00a0<\/p>\n<p>Chronic cough is highly prevalent in IPF patients, impacting up to 85% of the IPF population. There are ~140,000 U.S. IPF patients and the impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients&#8217; social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients.\u00a0<\/p>\n<p>Refractory chronic cough affects approximately 2-3 million adults in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly disruptive disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them. There are also no approved therapies for RCC in the U.S.\u00a0<\/p>\n<p>Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.<\/p>\n<p>For more information, visit <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4371012-1&amp;h=2100794004&amp;u=http%3A%2F%2Fwww.trevitherapeutics.com%2F&amp;a=www.TreviTherapeutics.com\" target=\"_blank\" rel=\"nofollow\">www.TreviTherapeutics.com<\/a>\u00a0and follow Trevi on <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4371012-1&amp;h=1397059099&amp;u=https%3A%2F%2Ftwitter.com%2FTreviThera&amp;a=X\" target=\"_blank\" rel=\"nofollow\">X<\/a>\u00a0(formerly Twitter) and <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4371012-1&amp;h=681187559&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Ftrevi-therapeutics-inc-%2F&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>.<\/p>\n<p>\n        <b>Investor Contact<br \/><\/b><br \/>\n        <span class=\"xn-person\">Jonathan Carlson<\/span><br \/>\n        <br \/>Trevi Therapeutics, Inc.<br \/>(203) 654 3286<br \/><a href=\"mailto:carlsonj@trevitherapeutics.com\" target=\"_blank\" rel=\"nofollow\">carlsonj@trevitherapeutics.com<\/a><\/p>\n<p>\n        <b>Media Contact<br \/><\/b><br \/>\n        <span class=\"xn-person\">Rosalia Scampoli<\/span><br \/>\n        <br \/>914-815-1465<br \/><a href=\"mailto:rscampoli@marketcompr.com\" target=\"_blank\" rel=\"nofollow\">rscampoli@marketcompr.com<\/a>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY28107&amp;sd=2025-02-27\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences-302386266.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences-302386266.html<\/a><\/p>\n<p>SOURCE  Trevi Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY28107&amp;Transmission_Id=202502270730PR_NEWS_USPR_____NY28107&amp;DateId=20250227\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW HAVEN, Conn. , Feb. 27, 2025 \/PRNewswire\/ &#8212;\u00a0Trevi Therapeutics, Inc.\u00a0(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC),\u00a0today announced that senior management will be attending the following investor conferences in March. TD Cowen 45th Annual Health Care Conference March 3-5, 2025, Boston, MassachusettsCorporate Presentation: March 4, 10:30-11:00am ETTrevi Representatives:\u00a0Lisa Delfini, Chief Financial Officer, and Farrell Simon, Chief Commercial OfficerA Corporate presentation is available for in-person conference attendees. Leerink Partners Global Healthcare Conference March 10-12, 2025, Miami, Florida Corporate Presentation: March 12, 8:00am ETTrevi Representatives:\u00a0Jennifer Good, President and CEO, and James Cassella, Chief Development OfficerA &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Trevi Therapeutics to Participate in Upcoming March Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-819067","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Trevi Therapeutics to Participate in Upcoming March Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trevi Therapeutics to Participate in Upcoming March Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW HAVEN, Conn. , Feb. 27, 2025 \/PRNewswire\/ &#8212;\u00a0Trevi Therapeutics, Inc.\u00a0(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC),\u00a0today announced that senior management will be attending the following investor conferences in March. TD Cowen 45th Annual Health Care Conference March 3-5, 2025, Boston, MassachusettsCorporate Presentation: March 4, 10:30-11:00am ETTrevi Representatives:\u00a0Lisa Delfini, Chief Financial Officer, and Farrell Simon, Chief Commercial OfficerA Corporate presentation is available for in-person conference attendees. Leerink Partners Global Healthcare Conference March 10-12, 2025, Miami, Florida Corporate Presentation: March 12, 8:00am ETTrevi Representatives:\u00a0Jennifer Good, President and CEO, and James Cassella, Chief Development OfficerA &hellip; Continue reading &quot;Trevi Therapeutics to Participate in Upcoming March Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-27T12:36:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Trevi Therapeutics to Participate in Upcoming March Investor Conferences\",\"datePublished\":\"2025-02-27T12:36:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/\"},\"wordCount\":502,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1504281\\\/Trevi_Therapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/\",\"name\":\"Trevi Therapeutics to Participate in Upcoming March Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1504281\\\/Trevi_Therapeutics_Logo.jpg\",\"datePublished\":\"2025-02-27T12:36:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1504281\\\/Trevi_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1504281\\\/Trevi_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trevi Therapeutics to Participate in Upcoming March Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trevi Therapeutics to Participate in Upcoming March Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Trevi Therapeutics to Participate in Upcoming March Investor Conferences - Market Newsdesk","og_description":"PR Newswire NEW HAVEN, Conn. , Feb. 27, 2025 \/PRNewswire\/ &#8212;\u00a0Trevi Therapeutics, Inc.\u00a0(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC),\u00a0today announced that senior management will be attending the following investor conferences in March. TD Cowen 45th Annual Health Care Conference March 3-5, 2025, Boston, MassachusettsCorporate Presentation: March 4, 10:30-11:00am ETTrevi Representatives:\u00a0Lisa Delfini, Chief Financial Officer, and Farrell Simon, Chief Commercial OfficerA Corporate presentation is available for in-person conference attendees. Leerink Partners Global Healthcare Conference March 10-12, 2025, Miami, Florida Corporate Presentation: March 12, 8:00am ETTrevi Representatives:\u00a0Jennifer Good, President and CEO, and James Cassella, Chief Development OfficerA &hellip; Continue reading \"Trevi Therapeutics to Participate in Upcoming March Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-27T12:36:35+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Trevi Therapeutics to Participate in Upcoming March Investor Conferences","datePublished":"2025-02-27T12:36:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\/"},"wordCount":502,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\/","name":"Trevi Therapeutics to Participate in Upcoming March Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg","datePublished":"2025-02-27T12:36:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Trevi Therapeutics to Participate in Upcoming March Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819067","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=819067"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819067\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=819067"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=819067"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=819067"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}